-
Leicester at risk of relegation after six-point deduction
-
Deadly storm sparks floods in Spain, raises calls to postpone Portugal vote
-
Trump urges new nuclear treaty after Russia agreement ends
-
'Burned in their houses': Nigerians recount horror of massacre
-
Carney scraps Canada EV sales mandate, affirms auto sector's future is electric
-
Emotional reunions, dashed hopes as Ukraine soldiers released
-
Bad Bunny promises to bring Puerto Rican culture to Super Bowl
-
Venezuela amnesty bill excludes gross rights abuses under Chavez, Maduro
-
Lower pollution during Covid boosted methane: study
-
Doping chiefs vow to look into Olympic ski jumping 'penis injection' claims
-
England's Feyi-Waboso in injury scare ahead of Six Nations opener
-
EU defends Spain after Telegram founder criticism
-
Novo Nordisk vows legal action to protect Wegovy pill
-
Swiss rivalry is fun -- until Games start, says Odermatt
-
Canadian snowboarder McMorris eyes slopestyle after crash at Olympics
-
Deadly storm sparks floods in Spain, disrupts Portugal vote
-
Ukrainian flag bearer proud to show his country is still standing
-
Carney scraps Canada EV sales mandate
-
Morocco says evacuated 140,000 people due to severe weather
-
Spurs boss Frank says Romero outburst 'dealt with internally'
-
Giannis suitors make deals as NBA trade deadline nears
-
Carrick stresses significance of Munich air disaster to Man Utd history
-
Record January window for transfers despite drop in spending
-
'Burned inside their houses': Nigerians recount horror of massacre
-
Iran, US prepare for Oman talks after deadly protest crackdown
-
Winter Olympics opening ceremony nears as virus disrupts ice hockey
-
Mining giant Rio Tinto abandons Glencore merger bid
-
Davos forum opens probe into CEO Brende's Epstein links
-
ECB warns of stronger euro impact, holds rates
-
Famine spreading in Sudan's Darfur, warn UN-backed experts
-
Lights back on in eastern Cuba after widespread blackout
-
Russia, US agree to resume military contacts at Ukraine talks
-
Greece aims to cut queues at ancient sites with new portal
-
No time frame to get Palmer in 'perfect' shape - Rosenior
-
Stocks fall as tech valuation fears stoke volatility
-
US Olympic body backs LA28 leadership amid Wasserman scandal
-
Gnabry extends Bayern Munich deal until 2028
-
England captain Stokes suffers facial injury after being hit by ball
-
Italy captain Lamaro amongst trio set for 50th caps against Scotland
-
Piastri plays down McLaren rivalry with champion Norris
-
ECB holds interest rates as strong euro causes jitters
-
EU close to sealing trade deal with Australia
-
German Cup final to stay in Berlin until 2030
-
What does Iran want from talks with the US?
-
Taming the lion: Olympians take on Bormio's terrifying Stelvio piste
-
Wind turbine maker Vestas sees record revenue in 2025
-
Italy's Casse tops second Olympic downhill training
-
Anti-doping boss 'uncomfortable' with Valieva's coach at Olympics
-
Bitcoin under $70,000 for first time since Trump's election
-
'I am sorry,' embattled UK PM tells Epstein victims
| RBGPF | 0.12% | 82.5 | $ | |
| RYCEF | -0.36% | 16.62 | $ | |
| AZN | 0.11% | 187.66 | $ | |
| BTI | 0.74% | 62.09 | $ | |
| GSK | 3.69% | 59.42 | $ | |
| CMSC | -0.04% | 23.51 | $ | |
| RIO | -4.92% | 91.96 | $ | |
| VOD | -7.27% | 14.645 | $ | |
| NGG | -0.94% | 86.975 | $ | |
| RELX | 1.36% | 30.19 | $ | |
| SCS | 0.12% | 16.14 | $ | |
| BP | -2.58% | 38.215 | $ | |
| BCC | -1.75% | 88.68 | $ | |
| JRI | -0.5% | 13.085 | $ | |
| CMSD | -0.08% | 23.85 | $ | |
| BCE | -3.13% | 25.54 | $ |
Novo Nordisk vows legal action to protect Wegovy pill
Novo Nordisk said Thursday it would take legal action against a US chain offering a copycat of the new pill version of its Wegovy weight-loss drug.
The Danish company only began selling Wegovy in pill form last month after having received approval from the US Food and Drug Administration, but the telehealth company Hims & Hers has begun advertising cheaper versions.
"This is another example of Hims & Hers' historic behaviour of duping the American public with knock-off GLP-1 products," said Novo Nordisk in a statement, referring to the hormone in Wegovy that regulates blood glucose levels and appetite.
"Novo Nordisk will take legal and regulatory action to protect patients, our intellectual property and the integrity of the US gold-standard drug approval framework," it added.
Limited production capacity for the blockbuster drug led the FDA to temporarily allow pharmacies to create so-called "compound" or copycat versions of Wegovy and Ozempic, an analogue used to treat diabetes.
That authorisation expired last May 22 but Novo Nordisk has complained of copycat versions of its drugs still being available.
Shares in Novo Nordisk have taken a beating this week after it warned of lower sales revenue in the United States as intensified competition pushes down prices.
V.F.Barreira--PC